Every year, more than 35,000 women in the UK alone undergo a mastectomy or lumpectomy due to breast cancer. Regenerys has a simpler, safer solution by developing a product and service that dramatically redesigned the current procedure and requires only the one adipose tissue harvest.
AptSci is dedicated to develop the aptamer technologies to generate high quality aptamers and in broad applications of research, diagnosis and therapeutics.
OPSL’s current pipeline of products are demonstrating the ability to substantially extend the organ transplant window, making distant donation more viable, improving the viability of transplant organs, and dramatically reducing pressure on transplant clinician teams.
MyO2 technology is in the cardiac space and aimed squarely at one of the largest problems currently facing cardiologists and interventional cardiac surgeons.
An NHS derived platform IP for the treatment of cardiac atrial fibrillation (AF), which could have a transformative effect on current treatment and outlook for patients suffering from AF.